TGTX 14.31 Tg Therapeutics $TGTX Hit a 52 week high of

New Post Public Reply Private Reply Replies (0) Message Board

Nov 13, 2014 at 2:07 PM

TGTX 14.31 Tg Therapeutics $TGTX Hit a 52 week high of 14.57 Closing the day 09:44 at 14.31 +0.28 +2.00% With a day low of 13.93 and a total volume of 123,894.

TGTX Recent Posts: http://investorshangout.com/TG-Therapeutics-Inc-TGTX-64219/

TGTX Tg Therapeutics Recent Headline News

5 Momentum Stocks Currently on the Move with More Potential Upside
at The Street - 1 hr 32 mins ago
Achillion, Groupon, Orexigen, Rackspace and TG Therapeutics have had strong recent moves and are showing no sign of slowing.
OREX: 5.95 (+0.11), RAX: 43.74 (+1.14), ACHN: 13.72 (-1.13), TGTX: 14.41 (+0.38), GRPN: 7.80 (-0.30)

Nasdaq stocks posting largest percentage increases
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
ICUI: 83.85 (-0.88), OREX: 5.95 (+0.11), PCMI: 8.82 (+0.02), CYAN: 6.31 (+0.33), ACHN: 13.72 (-1.13), TGTX: 14.41 (+0.38), AGIO: 86.54 (-0.33), LIOX: 5.21 (-0.22), SAJA: 6.21 (+0.31), PLNR: 6.77 (-0.38)

TG Therapeutics' (TGTX) CEO Michael Weiss on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 2:03PM CST

TGTX: 14.41 (+0.38)

TG Therapeutics net loss worsens in Q3
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 11:10AM CST

TGTX: 14.41 (+0.38)

TG Therapeutics posts 3Q loss
Automated Insights - Tue Nov 11, 4:11AM CST
NEW YORK (AP) _ TG Therapeutics Inc. (TGTX) on Tuesday reported a loss of $17.5 million, or 51 cents per share, in its third quarter.
TGTX: 14.41 (+0.38)

TG Therapeutics misses by $0.19
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 4:12PM CST

TGTX: 14.41 (+0.38)

TG Therapeutics, Inc. Announces Third Quarter 2014 Financial Results and Business Update
GlobeNewswire - Mon Nov 10, 3:20PM CST
TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for cancer and autoimmune diseases, today announced its results for the third quarter ended September 30, 2014 and recent company developments.
TGTX: 14.41 (+0.38)

TG Therapeutics reports November 11
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 3:10PM CST

TGTX: 14.41 (+0.38)

TG Therapeutics, Inc. to Host Conference Call on Third Quarter 2014 Financial Results and Business Update
GlobeNewswire - Fri Nov 07, 3:00PM CST
TG Therapeutics, Inc. (Nasdaq:TGTX), announced today that a conference call will be held on Tuesday, November 11, 2014 at 8:30am ET to discuss results for the third quarter of 2014 and provide a business outlook for the remainder of the year. Michael Weiss, Executive Chairman and Interim Chief Executive Officer, will host the call.
TGTX: 14.41 (+0.38)

TG Therapeutics, Inc. Announces Data Presentations at the Upcoming 56th American Society of Hematology Annual Meeting
GlobeNewswire - Thu Nov 06, 8:45AM CST
Combination of TG-1101, the Company's Novel Glycoenginereed Anti-CD20 Monoclonal Antibody and TGR-1202, the Company's Once Daily PI3K Delta Inhibitor to be Highlighted in Oral Presentation
TGTX: 14.41 (+0.38)

Strong On High Relative Volume: TG Therapeutics (TGTX)
at The Street - Mon Oct 27, 9:00AM CDT
Trade-Ideas LLC identified TG Therapeutics (TGTX) as a strong on high relative volume candidate
TGTX: 14.41 (+0.38)

Ligand Earns Milestone Payment on EU Approval of Noxafil - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 02, 12:00PM CDT
Ligand Pharmaceuticals Incorporated (LGND) earned a $550,000 milestone payment from partner Merck (MRK) on the EU approval of Noxafil (posaconazole) for infusion.
MRK: 59.37 (+0.06), TGTX: 14.41 (+0.38), LGND: 57.78 (+0.08), AMGN: 160.76 (-1.17)

TG Therapeutics reports exercise of its option to license the global rights to TGR-1202
M2 - Wed Sep 24, 6:17AM CDT
Biopharmaceutical company TG Therapeutics (NasdaqCM :TGTX) said on Tuesday that it has exercised its option to license the global rights to TGR-1202 from Rhizen Pharmaceuticals.
TGTX: 14.41 (+0.38)

Rhizen Pharmaceuticals Announces Out-licensing Agreement for TGR-1202, a Novel Next Generation PI3K-delta Inhibitor
GlobeNewswire - Tue Sep 23, 9:39AM CDT
Rhizen Pharmaceuticals S.A. today announced an out-licensing agreement for TGR-1202, a novel next generation PI3K-delta inhibitor. TG Therapeutics exercised its option for early conversion to a licensing agreement from a 50:50 joint venture partnership.
TGTX: 14.41 (+0.38)

TG Therapeutics Announces Exercise of License Option for Its Novel, Next Generation PI3K-Delta Inhibitor, TGR-1202
GlobeNewswire - Tue Sep 23, 6:30AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that it has exercised its option to license the global rights to TGR-1202, the Company's novel, next generation PI3K-delta inhibitor from Rhizen Pharmaceuticals, S A ("Rhizen"

. The Company and Rhizen have to date been jointly developing TGR-1202 in a 50:50 joint venture. Given the successful development of TGR-1202, TG Therapeutics elected an early exercise of the Company's license option.
TGTX: 14.41 (+0.38)

TG Therapeutics (TGTX) in Focus: Stock Gains 16.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 8:46AM CDT
TG Therapeutics (TGTX) was a big mover last session, with shares rising over 16% on the day.
ICUI: 83.85 (-0.88), ABAX: 54.98 (+0.78), TGTX: 14.41 (+0.38), EGRX: 12.59 (-0.21)

TG Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA for Its First Phase 3 Clinical Trial of TG-1101 (ublituximab) in Combination With Imbruvica(R) (ibrutinib) for Patients With Previously Treated Chronic Lymphocytic Leukemia
GlobeNewswire - Mon Sep 15, 6:08AM CDT
Overall Response Rate (ORR) to be the Primary Endpoint to Support Accelerated Approval with Progression-Free Survival (PFS) to Support Full Approval
TGTX: 14.41 (+0.38)

UPDATE -- TG Therapeutics, Inc. to Present at the 16th Annual Rodman & Renshaw Global Investment Conference
GlobeNewswire - Mon Sep 08, 3:28PM CDT
In a release issued earlier today by TG Therapeutics, Inc. (Nasdaq:TGTX), please note the company's scheduled presentation time has changed to 1:15 PM ET, from 1:40 PM ET previously. The updated release follows:
TGTX: 14.41 (+0.38)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tribal Tech Triumph: ILINX Boosts Proposal Efficiency

A New Era for Tribal Operations Well, here's a headline that might've slipped under your radar, but it’s got some serious implications. Over in Olympia, Washington, ImageSource, Inc., the brains behind the ILINX platform, just scored a home run with an automated system for crafting Tribal Indirect Cost Rate Proposals (ICRPs). This ain't just gadget talk; this is a...

FirstEnergy's New Tech to Bolster Pennsylvania Grid

Electricity Demand Spurs Grid Innovation The winds of change are blowing across Pennsylvania's power grid. FirstEnergy Transmission's (NYSE:FE) subsidiary, Keystone Appalachian Transmission Company (KATCo), is diving into a significant federally funded project to reinforce grid reliability. With electricity demand on an upward trajectory, Pennsylvania and beyond need...

EQT's Strategic Moves in Q3 2026 Amid Strong Execution

Inside EQT's Third Quarter Performance EQT Corporation has rolled out its third quarter 2026 results, and boy, they’ve been playing their cards with some finesse. The company's sporting a strong showing despite the tricky currents in the natural gas market where prices took a nosedive. What's keeping EQT upright, you ask? It's their smart marketing maneuvers and a...

Nektar Therapeutics Gears Up for Q3 Financial Reveal

Anticipation Builds as Nektar Preps Financial Report Ah, the life of a biotech investor, riding high or gripping the rail as tides turn with every quarterly report. This time, we're turning our gaze to Nektar Therapeutics and their Q3 financial results slated for release on November 12th, just as the market dust starts settling for the day. Now, if you’re wired to...

Ballard’s HPU Agile-H Poised to Transform Portable Energy

Another Step Forward with Hydrogen Ballard's got another ace up its sleeve with the HPU Agile-H. Now here’s the kicker—everyone’s scrambling for cleaner, more portable energy solutions, and Ballard’s stepped up. Born from their acquisition of GeoPura, this lightweight hydrogen powerhouse is engineered for those spots rudely ignored by the grid. Place your bets on...

Ameritas Hires Actuarial Veteran as VP in Strategic Move

Shifting Gears at Ameritas: New VP Takes the Helm Well, chalk one up for Ameritas on this move. They've just brought on Ying Zhao as the new vice president of actuarial and financial strategy. It's a mouthful of a title, sure, but it's the role itself that's worth watching. Ameritas, for those not tracking, is a major player in the insurance and financial universe, doing...

Heart Failure Certification Highlights Quality at Two Centers

Celebrating Milestones in Healthcare Certification Out there in the Bronx, two skilled nursing facilities just snagged a certification that means they're playing in the big leagues of heart failure care. Holliswood Center and Bushwick Center, both under the Centers Health Care umbrella, have been awarded the Skilled Nursing Facility Heart Failure Certification from none...

Genefluence Launches Rapid UTI PCR Test at Chelsea Hospital

There's a fresh breeze blowing through the dusty corridors of healthcare, shaking things up for the better. You see, Genefluence, the brainchild of Professor Chris Toumazou, isn't just throwing a bunch of tech jargon around—it's setting the stage for a much-needed shake-up in how we handle urinary tract infections (UTIs) and, believe me, it couldn’t have come sooner....

Rothera's KPI Swap Approval: A Financial Game Changer

Revolutionizing Risk Management with KPI Swaps Boy, if there's one thing that gets my ticker going, it's the buzz of innovation in financial markets. Rothera just landed a CFTC stamp of approval for something that's about to shake up how institutional traders manage risk: Key Performance Indicator (KPI) swaps. And can you believe it? This isn't just another derivative...

Envision Energy's AI System Targets Green Mining Future

The New Frontier: Mining's Green Shift Mining's bustling heart might just get an eco-friendly tune-up. That's the buzz Envision Energy stoked at All Energy Australia with their new AI-powered energy system aimed squarely at the mining and smelting industry. With wind, solar, battery storage, and all kinds of renewable gimmicks, they're striving to make those hulking...